Ibrutix 140 mg, containing the active ingredient Ibrutinib, is a targeted therapy indicated for the treatment of several B-cell malignancies:

• Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): For patients with previously treated or untreated disease, including those with 17p deletion.

• Waldenström Macroglobulinemia (WM): For symptomatic patients requiring therapy.

• Marginal Zone Lymphoma (MZL): For patients requiring systemic therapy who have received at least one prior anti-CD20-based therapy.

Ibrutix 140 mg is designed for patients who need effective, targeted treatment for these hematologic malignancies.

Description

Ibrutix 140 mg is an oral small-molecule Bruton’s Tyrosine Kinase (BTK) inhibitor. BTK is a critical enzyme in B-cell receptor (BCR) and cytokine receptor signaling pathways, promoting B-cell survival, proliferation, and migration. By irreversibly binding to a cysteine residue in the BTK active site, Ibrutix blocks BTK activity, disrupting downstream signaling and reducing malignant B-cell growth.

Pharmacology

Ibrutinib inhibits BTK-dependent pathways, which are essential for B-cell trafficking, chemotaxis, and adhesion. Preclinical studies demonstrate that Ibrutix suppresses malignant B-cell proliferation, survival, migration, and substrate adhesion both in vitro and in vivo. Its targeted mechanism allows for selective inhibition of cancerous B-cells while sparing most normal tissues, making it a cornerstone therapy for certain B-cell malignancies.

Dosage & Administration

• MCL and MZL: 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

• CLL/SLL and WM: 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

• CLL/SLL with bendamustine and rituximab: 420 mg (three 140 mg capsules) orally once daily during combination therapy cycles.

Administration: Take capsules orally at the same time each day. Swallow whole with water—do not open, break, or chew.

Drug Interactions

• CYP3A Inhibitors: Strong and moderate inhibitors may increase Ibrutix exposure; dose reduction may be required.

• CYP3A Inducers: Strong inducers may reduce efficacy; co-administration should be avoided.

Contraindications

• Hypersensitivity to Ibrutinib or any excipients.

Side Effects

Common adverse reactions include diarrhea, infections, cytopenias, atrial fibrillation, hypertension, hemorrhage, visual disturbances, second primary malignancies, and tumor lysis syndrome. Severe reactions may require dose adjustment or temporary discontinuation.

Pregnancy & Lactation

• Pregnancy: Ibrutix can cause fetal harm. Animal studies show embryofetal toxicity at doses 2–20 times clinical levels. Patients should be counseled on risks.

• Lactation: No data available; breastfeeding is not recommended during treatment.

Overdose

Limited human experience exists. In one case, a single dose of 1680 mg caused reversible Grade 4 liver enzyme elevation. Patients should be monitored carefully and receive supportive care if overdose occurs.

Special Populations

• Pediatric Use: Safety and efficacy not established.

• Geriatric Use: No significant differences in effectiveness; older patients may have higher risk of anemia or pneumonia.

• Hepatic Impairment: Metabolized in the liver; moderate to severe impairment is not recommended due to increased exposure. Monitor closely if mild impairment is present.

Therapeutic Class

Targeted Cancer Therapy

Storage Conditions

Store below 30°C in a dry place, protected from light. Keep out of reach of children.